Sanofi India Legal & Regulatory
Sanofi India received a GST show cause notice from Ahmedabad authorities for FY 2022-23. The notice proposes a tax, interest, and penalty demand totaling Rs.16.40 Crore.
- Value
- ₹16.40 Cr
ALFA Filings
Every announcement, straight from the exchange
Every Sanofi India legal & regulatory announcement on NSE and BSE, newest first, each with its own page.
Time
11 announcements with these filters
Sanofi India received a GST show cause notice from Ahmedabad authorities for FY 2022-23. The notice proposes a tax, interest, and penalty demand totaling Rs.16.40 Crore.
Sanofi India received a GST show cause notice alleging excess input tax credit claims. The total demand, including interest, is Rs. 23.74 Crore.
Sanofi India disclosed that the State Tax Officer, Tiruvallur dropped a ₹1.07 Crore GST demand for FY 2022-23. The company confirmed no material financial or operational impact.
The Supreme Court dismissed Sanofi India's petition to quash criminal proceedings. No penalty or operational restriction is imposed on the company at this stage.
Sanofi India Limited received a GST show cause notice regarding product classification for FY 2020-21. The total disputed demand, including tax and penalty, is ₹72.77 Crore.
Sanofi India received a GST refund of ₹1.32 Crore. The Deputy Commissioner also dropped an outstanding demand of ₹75.63 Lakh.
Sanofi India received a favorable income tax order vacating a demand of Rs. 0.73 Crore. The order drops proceedings related to non-deduction of TDS for AY 2019-20.
Sanofi India received a favourable Income Tax Appeal order dropping a demand of Rs. 72,71,510 for AY 2019‑20. The company says there is no material impact.
Sanofi India's refund claim of ₹0.12 Crore was rejected by State GST Ahmedabad. The company intends to file an appeal.
Sanofi India received a favorable order dropping a ₹0.11 Crore GST demand for FY 2018-19. The authority accepted the company's submissions, resulting in no material financial impact.
Tax authorities dropped a ₹0.60 Crore demand against Sanofi India regarding FY 2020-21 GST discrepancies. The resolution removes a potential liability with no material financial impact.